The GIST Group of Switzerland awarded its science prize for the third time on November 22, 2012. It has been awarded ex aequo to Dr. Daniel Perez, Memorial Sloan-Kettering Cancer Center (MSKCC), New York, USA, and Dr. Michael Montemurro, CHUV Lausanne/University Hospital Zurich.
The second annual GIST Day of Learning will be held on March 23, 2013. This year we are privileged once again that Dr. Jonathan Trent of Sylvester Cancer Center in Miami has agreed to host our gathering and we are honored to hear what he has to say.
Executive Director’s report focuses on better treatment options for GISTers For my Executive Director’s report, I usually highlight the many accomplishments of the Life Raft Group. Some of which include: Launching a GIST Day [...]
Lon Garber It all began in Africa with a pain in my backside. My wife, Val, jokingly called it payback time since I’d been a pain in her backside for 37 years. The [...]
By Drs. Sebastian Bauer, West German Cancer Center, University of Essen, Germany and Jonathan Fletcher, Brigham & Women’s Hospital, Harvard University, LRG Research Team Researchers talk plainly about microGISTs, how this cancer develops and what all [...]
Here is a handy snapshot of how the proposed affordable care act impacts GIST patients.
Caring for someone suffering from an illness is hard, there's no other way to put it. Most of the time it gets easier but in the beginning right after a surgery, it can be very emotionally draining and frightening. Caring for someone you love is even more so as there is an emotional connection, a deep desire to alleviate the pain and suffering we see in the eyes of the person whose bedside we are hovering over.
Two posters were presented by principal investigators in the Phase 2 and 3 trials of masitinib for the treatment of newly diagnosed GIST patients.
Life Raft Group member Jason DeLorenzo held his annual “DeLoBQ” fundraiser last month in Alexandria, Virginia. The BBQ has raised almost $2,000 thus far, and donations are still coming! Jason explains the growing success of [...]
An agreement to secure the entry of Gleevec for Guatemalan GIST and chronic myeloid leukemia patients was reached with the Central American country’s government July 10, following advocacy efforts by Novartis Pharmaceuticals, Alianza GIST and [...]
